国家参考实验室的促甲状腺激素受体抗体检测利用模式:TRAb、TSI还是两者联用?
基于超过189 000例患者就诊的TRAb与TSI检测订单,评估配对检测的频率、一致性及临床相关性。TRAb与TSI在14.3%的TRAb/TSI-BA订单和17.4%的TRAb/TSI-Br订单中被同时开具;定性比较显示TRAb与TSI-BA配对订单中12.5%(1590例)不一致,TRAb与TSI-Br配对订单中6.6%(1149例)不一致。配对订单使潜在不必要的检测成本增加31%至325%。作者认为在自身免疫性甲状腺功能亢进评估中配对检测TRAb和TSI是冗余的。
要点
- TRAb与TSI-BA在同一就诊中同时开具的比例为14.3%,TRAb与TSI-Br为17.4%。
- TRAb与TSI-BA配对订单的不一致率为12.5%(1590例),TRAb与TSI-Br为6.6%(1149例)。
- 配对订单使潜在不必要的检测成本增加31%至325%。
核心结论
- TRAb与TSI检测之间观察到良好的临床和分析一致性,表明在自身免疫性甲状腺功能亢进的评估中配对开具TRAb和TSI是冗余的。
- 在大多数情况下使用单一检测评估TRAb是合适的,并可能节省大量医疗费用。
研究设计与样本
- 分析了超过189 000例同时有TRAb和TSI生物分析法(TSI-BA)或TSI桥接免疫分析法(TSI-Br)检测订单的患者就诊,以评估配对订单频率和TRAB/TSI定性一致性。
- 对部分患者进行了病历审查以进行临床相关性分析。
- 进行了成本分析以估计不必要的配对检测带来的经济负担。
主要发现
- TRAb与TSI在同一就诊中同时开具的比例为14.3%(TRAb/TSI-BA订单)和17.4%(TRAb/TSI-Br订单)。
- 定性比较显示TRAb与TSI-BA配对订单中12.5%(1590例)不一致,TRAb与TSI-Br配对订单中6.6%(1149例)不一致。
- 根据患者游离甲状腺素和TSH浓度及疾病状态,TSI检测与甲状腺功能亢进和确诊Graves病的诊断更一致。
- 配对订单导致潜在不必要的检测成本增加31%至325%。
临床怎么用
- 作者认为在大多数情况下使用单一检测评估TRAb是合适的,并可能节省大量医疗费用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There are currently 2 classes of thyroid-stimulating hormone receptor (TSHR) antibody assays, namely TSHR antibody (TRAb) assays and thyroid-stimulating immunoglobulin (TSI) assays. Clinical guidelines do not currently specify appropriate use of TSHR autoantibody tests in the diagnosis of hyperthyroidism, which may result in paired orders for both tests with the possibility of discordant results and excessive costs. OBJECTIVE: This work aimed to evaluate the clinical and analytical redundancy of paired TSHR autoantibody testing-specifically TRAb and TSI assays-in the diagnosis of autoimmune-mediated hyperthyroidism, by analyzing the frequency of paired orders, assay concordance, and clinical correlation across a large cohort of patient encounters. METHODS: Over 189 000 patient encounters with TRAb and TSI bioassay (TSI-BA) or TSI bridge immunoassay (TSI-Br) test orders were examined to assess the frequency of paired orders and qualitative agreement of TRAB/TSI. A chart review was performed on a subset of patients for clinical correlation. Lastly, a cost analysis was performed to estimate the financial burden of unnecessary paired testing. RESULTS: TRAb and TSI were co-ordered on the same encounter in 14.3% of TRAb/TSI-BA orders and 17.4% of TRAb/TSI-Br orders. Qualitative comparison showed discordance in 12.5% (1590) of TRAb and TSI-BA paired orders and 6.6% (1149) of TRAb and TSI-Br paired orders. Based on patient free thyroxine and TSH concentrations and disease status, the TSI assays aligned better with hyperthyroidism and confirmed Graves disease diagnoses. Paired orders resulted in a 31% to 325% increase in potentially unnecessary testing costs. CONCLUSION: We observed good clinical and analytical agreement between TRAb and TSI assays, suggesting that paired orders for TRAb and TSI are redundant in the assessment of autoimmune-mediated hyperthyroidism. Use of a single test to assess TRAb would be appropriate in most scenarios and may lead to considerable savings of health care dollars.
引用
- Nelson HA, Doyle K, Straseski JA, et al. TSH Receptor Antibody Test Utilization Patterns From a National Reference Laboratory: TRAb, TSI, or Both? J Clin Endocrinol Metab. 2025. PMID: 40482060. doi:10.1210/clinem/dgaf330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。